Tag
Some psoriatic arthritis patients may be able to take a common TNF inhibitor drug less frequently and still maintain remission.
On Dec. 14, Pfizer, which makes tofacitinib (Xeljanz), announced that the FDA had approved the drug for PsA.
The U.S. Food and Drug Administration is currently reviewing Simponi, an intravenous TNF-inhibitor, for psoriatic arthritis and ankylosing spondylitis patients.
I am a 57-year-old woman who has been living with psoriasis and psoriatic arthritis since the age of five. I got my first job at age 14, and have been going strong ever since. When I started my very first...
In looking back, my journey with psoriatic arthritis and osteoarthritis probably started in my 20’s, however, I wasn’t diagnosed until my late 40’s. When I was finally diagnosed I was very angry at the doctors that I had seen over the...